A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : EZH2 / enhancer of zeste 2

[Related PubMed/MEDLINE]
Total Number of Papers: 52
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   EZH2  (>> Co-occurring Abbreviation)
Long Form:   enhancer of zeste 2
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 The EZH2 SANT1 domain is a histone reader providing sensitivity to the modification state of the H4 tail. H4K16, H4K20, PRC2, SRM
2018 ANRIL regulates production of extracellular matrix proteins and vasoactive factors in diabetic complications. ANRILKO, DCM, DN, ECM, FN, PRC2
2018 microRNA-124a suppresses PHF19 over-expression, EZH2 hyper-activation, and aberrant cell proliferation in human glioma. PHF19, PRC2
2018 Pharmacological inhibition of EZH2 disrupts the female germline epigenome. ---
2018 Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator. AR, PRC2
2018 The SLC34A2-ROS-HIF-1-induced upregulation of EZH2 expression promotes proliferation and chemo-resistance to apoptosis in colorectal cancer. HIF-1, ROS
2018 TSPYL2 Regulates the Expression of EZH2 Target Genes in Neurons. ChIP, H3K27me3, TSPYL2
2017 Multicellular Tumor Spheroids Combined with Mass Spectrometric Histone Analysis To Evaluate Epigenetic Drugs. EZH1, MALDI, MCTS, MS, PRC2, PTMs
2017 n-Butylidenephthalide Regulated Tumor Stem Cell Genes EZH2/AXL and Reduced Its Migration and Invasion in Glioblastoma. AXL, BP, CSCs, EMT, GBM
10  2017 Targeting Chromatin Remodeling in Inflammation and Fibrosis. BRD4, CDK, EMT, IRF1, NF-kappaB, ZEB1
11  2016 Association of Enhancer of Zeste 2 (EZH2) Genotypes with Bladder Cancer Risk in Taiwan. ---
12  2016 Developmental exposure to endocrine disrupting chemicals alters the epigenome: Identification of reprogrammed targets. BPA, DES, DNMTs, EDCs, EEDs, ERs, H3K9, HMTs
13  2016 Early Life Adverse Environmental Exposures Increase the Risk of Uterine Fibroid Development: Role of Epigenetic Regulation. DES, Med12
14  2016 EZH2, an on-off valve in signal network of tumor cells. ---
15  2016 HIFI-alpha activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. EED, FOXM1, MMPs, PRC2, SUZ12
16  2016 Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays. PRC2
17  2016 Long non-coding RNA HoxA-AS3 interacts with EZH2 to regulate lineage commitment of mesenchymal stem cells. lncRNAs, MSCs
18  2016 MicroRNA-298 inhibits malignant phenotypes of epithelial ovarian cancer by regulating the expression of EZH2. EOC
19  2016 Prognostic significance of EZH2 expression in patients with oesophageal cancer: a meta-analysis. PRC2
20  2016 Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression. PTs
21  2015 Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer. CRC, DFS, EED, SUZ12
22  2015 EZH2 promotes progression of small cell lung cancer by suppressing the TGF-beta-Smad-ASCL1 pathway. ASCL1, TbetaRII, TGF-beta
23  2015 NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2. PRC2
24  2015 Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. pT416-EZH2, TNBC
25  2015 Prognostic significance of EZH2 expression in patients with digestive cancers: a meta-analysis. PRC2
26  2015 Regulation of the expression of claudin 23 by the enhancer of zeste 2 polycomb group protein in colorectal cancer. ChIP, CLDN23, CRC
27  2015 The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer. ---
28  2014 EZH2 genetic variants affect risk of gastric cancer in the Chinese Han population. AOR, PRC2, SNP
29  2014 PCI-24781 down-regulates EZH2 expression and then promotes glioma apoptosis by suppressing the PIK3K/Akt/mTOR pathway. mTOR, p70S6K, PI3K
30  2013 A quantitative atlas of histone modification signatures from human cancer cells. PTMs
31  2013 Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. CCND1, EOC
32  2013 Effects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma. HCC
33  2013 Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. GBMs, PcG
34  2013 Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. ATRT, PRC2
35  2013 Maternal obesity induces epigenetic modifications to facilitate Zfp423 expression and enhance adipogenic differentiation in fetal mice. CON, MO, OB
36  2013 The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination. H2B
37  2012 Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. miRNA
38  2012 EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. NSCLC, siRNA
39  2012 Fasting of 3-day-old chicks leads to changes in histone H3 methylation status. CRH, HMT, PO/AH, PVN, TRH
40  2012 Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression. ---
41  2012 Polycomb antagonizes p300/CREB-binding protein-associated factor to silence FOXP3 in a Kruppel-like factor-dependent manner. KLF
42  2011 Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. GBM, GSC, HDAC, PRC2, SAHA
43  2011 Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. HDACs, LTR, PRC2
44  2011 EZH2 depletion blocks the proliferation of colon cancer cells. RNAi
45  2010 Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. AD, AI
46  2010 Deregulation of EZH2 expression in human spermatogenic disorders and testicular germ cell tumors. CIS, TGCT
47  2009 Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. BPH1
48  2006 Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast. ---
49  2006 Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. AML, EED, H3K27, SUZ12
50  2005 Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. ---
51  2005 Expression of Polycomb-group genes in human ovarian follicles, oocytes and preimplantation embryos. EED, EED, PcG, YY1
52  2004 Polycomb group suppressor of zeste 12 links heterochromatin protein 1alpha and enhancer of zeste 2. HP1alpha, PcG